533 related articles for article (PubMed ID: 25613538)
1. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
2. Validation of simplified dosimetry approaches in ⁸⁹Zr-PET/CT: the use of manual versus semi-automatic delineation methods to estimate organ absorbed doses.
Makris NE; van Velden FH; Huisman MC; Menke CW; Lammertsma AA; Boellaard R
Med Phys; 2014 Oct; 41(10):102503. PubMed ID: 25281978
[TBL] [Abstract][Full Text] [Related]
3. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
4. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT.
Beauregard JM; Croteau E; Ahmed N; van Lier JE; Bénard F
J Nucl Med; 2009 Jan; 50(1):100-7. PubMed ID: 19091905
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
[TBL] [Abstract][Full Text] [Related]
6. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
7. An automatic delineation method for bone marrow absorbed dose estimation in (89)Zr PET/CT studies.
Makris NE; Boellaard R; Menke CW; Lammertsma AA; Huisman MC
EJNMMI Phys; 2016 Dec; 3(1):13. PubMed ID: 27447823
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
[TBL] [Abstract][Full Text] [Related]
9. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.
Zanzonico PB; Finn R; Pentlow KS; Erdi Y; Beattie B; Akhurst T; Squire O; Morris M; Scher H; McCarthy T; Welch M; Larson SM; Humm JL
J Nucl Med; 2004 Nov; 45(11):1966-71. PubMed ID: 15534070
[TBL] [Abstract][Full Text] [Related]
10. Radiation dose estimates in humans for (11)C-acetate whole-body PET.
Seltzer MA; Jahan SA; Sparks R; Stout DB; Satyamurthy N; Dahlbom M; Phelps ME; Barrio JR
J Nucl Med; 2004 Jul; 45(7):1233-6. PubMed ID: 15235071
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and Radiation Dosimetry of
Garg PK; Lokitz SJ; Nazih R; Garg S
J Nucl Med; 2017 Mar; 58(3):473-478. PubMed ID: 27660145
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.
Bretin F; Bahri MA; Bernard C; Warnock G; Aerts J; Mestdagh N; Buchanan T; Otoul C; Koestler F; Mievis F; Giacomelli F; Degueldre C; Hustinx R; Luxen A; Seret A; Plenevaux A; Salmon E
Mol Imaging Biol; 2015 Aug; 17(4):557-64. PubMed ID: 25595813
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.
Doss M; Kolb HC; Zhang JJ; Bélanger MJ; Stubbs JB; Stabin MG; Hostetler ED; Alpaugh RK; von Mehren M; Walsh JC; Haka M; Mocharla VP; Yu JQ
J Nucl Med; 2012 May; 53(5):787-95. PubMed ID: 22499613
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and estimation of radiation-absorbed doses in humans for 13N-ammonia PET.
Yi C; Yu D; Shi X; He Q; Zhang X; Zhang X
Ann Nucl Med; 2015 Nov; 29(9):810-5. PubMed ID: 26243501
[TBL] [Abstract][Full Text] [Related]
16. (S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry.
Smolarz K; Krause BJ; Graner FP; Wagner FM; Hultsch C; Bacher-Stier C; Sparks RB; Ramsay S; Fels LM; Dinkelborg LM; Schwaiger M
J Nucl Med; 2013 Jun; 54(6):861-6. PubMed ID: 23568366
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Imaging agent for single photon emission computed tomography.
Sathekge M; Wagener J; Smith SV; Soni N; Marjanovic-Painter B; Zinn C; Van de Wiele C; D'Asseler Y; Perkins G; Zeevaart JR
Nuklearmedizin; 2013 Dec; 52(6):222-7. PubMed ID: 24108524
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow dosimetry using 124I-PET.
Schwartz J; Humm JL; Divgi CR; Larson SM; O'Donoghue JA
J Nucl Med; 2012 Apr; 53(4):615-21. PubMed ID: 22414633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
